Literature DB >> 2206784

Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis.

C Merkel1, M Bolognesi, P Angeli, G F Finucci, P Amodio, S Bellon, A Gatta.   

Abstract

1. Vasodilators are currently under investigation as possible therapeutic agents in the treatment of portal hypertension. Among them calcium-channel antagonists and organic nitrates have been of particular interest. Few and conflicting data, however, have been reported on their effect on liver function. 2. Twenty patients with biopsy-proven alcoholic cirrhosis were studied before and 25-35 min following the acute administration of 5 mg verapamil i.v. (eight patients) or 5 mg isosorbide dinitrate sublingually (12 patients). The plasma clearance of indocyanine green (ICG) and its intrinsic hepatic clearance were used as indices of liver function. Seven further patients were investigated before and after a placebo infusion according to the same methodology. 3. No significant change in ICG kinetics was found after verapamil or isosorbide dinitrate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206784      PMCID: PMC1368221          DOI: 10.1111/j.1365-2125.1990.tb03768.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.

Authors:  J G Freeman; J R Barton; C O Record
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

2.  Statistics in practice. Comparing the means of several groups.

Authors:  K Godfrey
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

3.  Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.

Authors:  R Hallemans; R Naeije; P Mols; C Mélot; P Reding
Journal:  Crit Care Med       Date:  1983-07       Impact factor: 7.598

4.  A method of determining intrinsic hepatic clearance from the first-pass effect.

Authors:  L Bass; K Winkler
Journal:  Clin Exp Pharmacol Physiol       Date:  1980 May-Jun       Impact factor: 2.557

5.  Hepatic circulation during sodium nitroprusside infusion in the carbon tetrachloride-treated dog.

Authors:  S Gelman; E A Ernst
Journal:  Ala J Med Sci       Date:  1982-10

6.  Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response.

Authors:  A T Blei; J Gottstein
Journal:  Hepatology       Date:  1986 Jan-Feb       Impact factor: 17.425

7.  Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.

Authors:  R J Groszmann; D Kravetz; J Bosch; M Glickman; J Bruix; J Bredfeldt; H O Conn; J Rodes; E H Storer
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

8.  Intravascular oesophageal variceal pressure (IOVP) assessed by endoscopic fine needle puncture under basal conditions, Valsalva's manoeuvre and after glyceryltrinitrate application.

Authors:  M Staritz; T Poralla; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

9.  Hepatic plasma flow during sodium nitroprusside-induced hypotension in humans.

Authors:  M Chauvin; F Bonnet; C Montembault; M Lafay; P Curet; P Viars
Journal:  Anesthesiology       Date:  1985-09       Impact factor: 7.892

10.  Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow.

Authors:  C K Svensson; J C Cumella; M Tronolone; E Middleton; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

View more
  2 in total

1.  Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.

Authors:  A L Jones; I H Bangash; J Walker; K J Simpson; N D Finlayson; P C Hayes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

Review 2.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.